OncoSwift® Breast Multi-Omics
Unique Identifier:
ML-S003
Name on Requisition:
OncoSwift® Breast Multi-Omics
Product Line:
ST
Panel Group:
Solid Tumor Panels
Panel Name:
OncoSwift® Breast Multi-Omics
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
AR, AKT1, ATM, BRAF, BRCA1, BRCA2, CCNE1, CDH1, CDK12, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FANCA, FANCL, FGFR1, FGFR2, FGFR3, KRAS, MLH1, MRE11A, MSH2, MSH6, MUTYH, MYC, NBN, NTRK1, NTRK2, NTRK3, PALB2, PIK3CA, PMS2, PTEN, RAD50, RAD51, RB1, RET, STK11, TERT, TP53
Disease:
breast carcinoma
The OncoSwift® Breast Multi-Omics Panel targets clinically relevant biomarkers in breast carcinoma, including hormone receptor signaling and HER2 pathways. Through combined DNA and RNA-based testing, the panel detects mutations, fusions, and expression changes, supporting molecular subtyping, prognosis, and eligibility for targeted therapies such as endocrine and HER2-directed agents.
Specimen Requirements
Preparation:
FFPE tissue or slides
Collection:
In case of FFPE sections, 5-10 sections are recommended at 4 to 10 micron.
Stability:
Stored at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Bacterial over growth. Submitted with incomplete requisition form (unless a requisition is subsequently sent). Unlabeled or improperly labeled specimens, without contact information or when failing to
reach the ordering physician for clarification. Decalcified specimens. Improperly stored DNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Slides may be stored at ambient
CPT(s)
81459
New York Approved
Yes
TAT
7
Requisition Type
ST
Levels of Service
Full
DexS Code
C05C8
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
